Advertisement

Imedex® is an industry leader in providing accredited, independent continuing medical education to health care professionals.

April 17-18, 2015

New York, New York

Advertisement

Scientific Agenda

Friday, April 17, 2015

8:00 am

Introduction and pre-activity audience survey

Session I: Plasma Cell Disorders

Session Chair: Robert Z. Orlowski, MD, PhD

8:10 am

Lecture: The future of antibody therapies and drug conjugates in multiple myeloma
Sagar Lonial, MD

8:40 am

Debate: Are two or three drugs a reasonable frontline regimen for newly diagnosed transplant ineligible myeloma?

Two drugs
Sagar Lonial, MD

Three drugs
Paul Richardson, MD

9:10 am

Debate: Which is optimal as induction therapy for newly diagnosed transplant eligible myeloma?

Triplet regimens
Paul Richardson, MD

Quadruplet regimens
Ruben Niesvizky, MD

9:40 am

Break

9:55 am

Lecture: Emerging small molecule therapies with promise
Robert Z. Orlowski, MD, PhD

10:20 am

Challenging Cases in Multiple Myeloma Panel

11:05 am

Debate: Should consolidation therapy and minimal residual disease testing be used for monitoring and treatment?
Yes
Suzanne Lentzsch, MD, PhD

No
Sagar Lonial, MD

11:35 pm

Debate:What is optimal maintenance therapy duration for a newly diagnosed multiple myeloma patients completing induction, ASCT and consolidation?
Maintenance for 2 years only
Suzanne Lentzsch, MD, PhD


Continuous maintenance therapy
Ruben Niesvizky, MD

12:05 pm

Final remarks and post-activity audience survey

12:15 pm

Lunch

Session II: Chronic Lymphocytic Leukemia

Session Chair: David P. Steensma, MD

2:00 pm

Debate: What is the best frontline regimen for a CLL patient aged 60 who requires therapy?
FCR
Matthew S. Davids, MD, MMSc

Ibrutinib-based treatment without chemotherapy
Richard R. Furman, MD

2:30 pm

Lecture: New anti-CD20 antibodies for CLL – are they better than rituximab?
Bruce D. Cheson, MD

2:55 pm

Debate: What is the best approach for a patient with multiple relapsed CLL after chemoimmunotherapy
Allogeneic stem cell transplant
Koen Van Besien MD

Kinase inhibitor therapy
Bruce D. Cheson, MD

Other novel agents
Matthew S. Davids, MD, MMSc

3:40 pm

Break

Session III: Chronic Myeloid Leukemia

Session Chair: David P. Steensma, MD

3:55 pm

Lecture: Management of thrombosis risk with ponatinib and other TKIs for CML?
Javid Moslehi, MD

4:20 pm

Lecture: How should chronic-phase CML management be influenced by RT-PCR results at 3 months and beyond?
Jeffrey H. Lipton, MD, PhD, FRCPC

4:45 pm

Lecture: Who should still be transplanted for CML in 2015?
Jerry P. Radich, MD

5:10 pm

Final remarks and post-activity audience survey

5:15 pm

Adjourn

Saturday, April 18, 2015

8:00 am

Welcome and pre-activity audience survey

Session IV: Not-So-Benign Hematology

Session Chair: David P. Steensma, MD

8:10 am

Lecture: Evaluation of minor prolongation of coagulation times
Ken A. Bauer, MD

8:35 am

Lecture: Treatment and prevention of heparin-induced thrombocytopenia
Lawrence Rich, MD

9:00 am

Lecture: Anticoagulation Management and Difficult Cases
Jean M. Connors, MD

Session V: Acute Leukemia

Session Chair: David P. Steensma, MD

9:25 am

Lecture: An overview of new therapies for ALL
Dan J. DeAngelo, MD, PhD

9:50 am

Break

Session VI: MPNs and MDS

Session Chair: David P. Steensma, MD

10:05 am

Lecture: Management of lower-risk MDS without del5q and refractory to ESAs
Amy E. DeZern, MD, MHS

10:30 am

Lecture: IPSS, DIPSS, DIPSS-Plus, MISPS, GIPSS: making sense of the tangled web of prognostic scoring systems in MF
John Mascarenhas, MD

10:55 am

Debate: Should JAK2 inhibitors be used for lower-risk MF, or only on-label (higher-risk)?
Yes
Ruben A. Mesa, MD


More data is needed
John Mascarenhas, MD

11:25 am

Lecture: Management of MDS patients for whom a hypomethylating agent has failed
David Steensma, MD

11:50 am

Final remarks and post-activity audience survey

12:00 pm

Lunch

Session VII: Lymphomas

Session Chair: John P. Leonard, MD

1:30 pm

Welcome and pre-activity audience survey

1:35 pm

Debate: A 48-year-old woman is diagnosed with mildly symptomatic, low tumor burden, stage IV follicular lymphoma, low risk FLIPI score and desires treatment. What would you recommend to her?
R-CHOP or B-R
Peter Martin, MD


Single agent rituximab or a combination “biologic doublet” therapy
Bruce Cheson, MD

2:05 pm

Debate: A 60 year old man with stage I (excised) follicular lymphoma, now NED. How should he be treated?
Observation
Morton Coleman, MD


Radiation therapy, with or without systemic treatment
Jonathan Friedberg MD

2:35 pm

Lecture: Kinase inhibitors and immunomodulatory drugs – What does the future hold for lymphomas?
John P. Leonard, MD

3:00 pm

Break

3:15 pm

Debate: How should a 63 year old male with advanced stage, low risk MIPI mantle cell be treated outside of a clinical trial?
Chemoimmunotherapy with AutoSCT -
Koen van Besien, MD, PhD


Chemotherapy-based therapy without transplant
John P. Leonard, MD

3:45 pm

Lecture: Double hit lymphoma. What is it and how should we treat it?
Jonathan Friedberg, MD

4:10 pm

Debate: Should we treat patients with DLBCL differently today based on cell of origin (Germinal Center/Non-Germinal Center)?
Yes
Richard I. Fisher, MD

No
Peter Martin, MD

4:40 pm

Lecture: Radiation in Hodgkin Lymphoma – Who should get it, who should not get it?
David Straus, MD

5:05 pm

Debate: What is the optimal management for a 65 year old patient with peripheral T cell lymphoma relapsed after upfront chemotherapy?
Stem cell transplantation (allo or auto)
Barbara Pro, MD

Sequential novel agents
Jia Ruan, MD, PhD

5:35 pm

Final remarks and post-activity audience survey

5:40 pm

Adjourn